BioCentury | Jan 12, 2021
Finance

Diverse syndicate stands behind EQRx’s mission with $500M series B round

...Arch Venture Partners, Andreessen Horowitz, Casdin Capital, Section 32...
BioCentury | Jul 30, 2020
Product Development

Thrive to leverage $257M series B to make case for broad access to CancerSEEK blood test

...to design and run a registrational trial for its multicancer blood diagnostic. Casdin Capital and Section 32...
...of CancerSEEK in 9,911 evaluable participants, enrolled only women, 94.9% of whom were non-Hispanic white. Section 32...
BioCentury | Jul 15, 2020
Emerging Company Profile

Glympse raises $47.6M to test biosensors that could improve on liver biopsies in NASH

...forward into infectious diseases. On Wednesday, Glympse announced the closing of the series B round. Section 32...
...at the intersection of biology, engineering and machine learning, and our investors represent that intersection.” Section 32...
...SIX:ROG; OTCQX:RHHBY) in 2018. Foundation Medicine CEO Mike Pellini is also a managing partner at Section 32...
BioCentury | Jun 10, 2020
Emerging Company Profile

Autobahn: fine-tuning thyroid agonism to remyelinate axons

...round are BVF Partners, Biogen Inc. (NASDAQ:BIIB), Bristol Myers Squibb Co. (NYSE:BMY), Pfizer Ventures, Invus, Section 32...
...Investments, BVF Partners L.P., Biogen Inc. (NASDAQ:BIIB), Bristol Myers Squibb Co. (NYSE:BMY), Pfizer Ventures, Invus, Section 32...
BioCentury | Apr 1, 2020
Emerging Company Profile

Aspen plans to drive iPS cell therapy into Parkinson’s patients with $70M A round

...series A round led by OrbiMed Advisors. Existing investors Arch Venture Partners, Domain Associates and Section 32...
...Altman, Section 32 CEO: Howard Federoff Patents: 1 issued Lauren Martz, Senior Editor Aspen Neuroscience Inc. OrbiMed Advisors Domain Associates LLC Section 32 Frazier...
BioCentury | Mar 6, 2020
Finance

March 5 Quick Takes: Zogenix, Karyopharm, BridgeBio, Cinclus, Culture Biosciences, Deerfield-Melinta

...led the round with participation from The Production Board and existing investors Verily Life Sciences, Section 32...
BioCentury | Feb 6, 2020
Finance

Feb. 5 Financial Quick Takes: Aimmune gets $200M Nestlé investment; plus Vineti, MaaT, Kezar, Ziopharm, Ikarovec

...unit of Gilead Sciences Inc. (NASDAQ:GILD), as well as existing investors Canaan Partners, Threshold Ventures, Section 32...
BioCentury | Jan 22, 2020
Emerging Company Profile

Relay’s protein motion platform approaches clinical starting line

...employees: About 120 Funds raised: $520 million Investors: Third Rock Ventures, D.E. Shaw Research, GV, Section 32...
BioCentury | Jan 12, 2020
Emerging Company Profile

Borisy newco aims to offer ‘radically’ cheaper drugs by disrupting biopharma’s traditional model

...$200 million in series A funding from GV, Arch Venture Partners, Andreessen Horowitz, Casdin Capital, Section 32...
BioCentury | Dec 13, 2019
Finance

Aspen’s debut reveals first cell therapy investment by Domain

...declined to disclose a fund-raising target. Alexandria Venture Investments, Arch Venture Partners, OrbiMed Advisors and Section 32...
Items per page:
1 - 10 of 34
BioCentury | Jan 12, 2021
Finance

Diverse syndicate stands behind EQRx’s mission with $500M series B round

...Arch Venture Partners, Andreessen Horowitz, Casdin Capital, Section 32...
BioCentury | Jul 30, 2020
Product Development

Thrive to leverage $257M series B to make case for broad access to CancerSEEK blood test

...to design and run a registrational trial for its multicancer blood diagnostic. Casdin Capital and Section 32...
...of CancerSEEK in 9,911 evaluable participants, enrolled only women, 94.9% of whom were non-Hispanic white. Section 32...
BioCentury | Jul 15, 2020
Emerging Company Profile

Glympse raises $47.6M to test biosensors that could improve on liver biopsies in NASH

...forward into infectious diseases. On Wednesday, Glympse announced the closing of the series B round. Section 32...
...at the intersection of biology, engineering and machine learning, and our investors represent that intersection.” Section 32...
...SIX:ROG; OTCQX:RHHBY) in 2018. Foundation Medicine CEO Mike Pellini is also a managing partner at Section 32...
BioCentury | Jun 10, 2020
Emerging Company Profile

Autobahn: fine-tuning thyroid agonism to remyelinate axons

...round are BVF Partners, Biogen Inc. (NASDAQ:BIIB), Bristol Myers Squibb Co. (NYSE:BMY), Pfizer Ventures, Invus, Section 32...
...Investments, BVF Partners L.P., Biogen Inc. (NASDAQ:BIIB), Bristol Myers Squibb Co. (NYSE:BMY), Pfizer Ventures, Invus, Section 32...
BioCentury | Apr 1, 2020
Emerging Company Profile

Aspen plans to drive iPS cell therapy into Parkinson’s patients with $70M A round

...series A round led by OrbiMed Advisors. Existing investors Arch Venture Partners, Domain Associates and Section 32...
...Altman, Section 32 CEO: Howard Federoff Patents: 1 issued Lauren Martz, Senior Editor Aspen Neuroscience Inc. OrbiMed Advisors Domain Associates LLC Section 32 Frazier...
BioCentury | Mar 6, 2020
Finance

March 5 Quick Takes: Zogenix, Karyopharm, BridgeBio, Cinclus, Culture Biosciences, Deerfield-Melinta

...led the round with participation from The Production Board and existing investors Verily Life Sciences, Section 32...
BioCentury | Feb 6, 2020
Finance

Feb. 5 Financial Quick Takes: Aimmune gets $200M Nestlé investment; plus Vineti, MaaT, Kezar, Ziopharm, Ikarovec

...unit of Gilead Sciences Inc. (NASDAQ:GILD), as well as existing investors Canaan Partners, Threshold Ventures, Section 32...
BioCentury | Jan 22, 2020
Emerging Company Profile

Relay’s protein motion platform approaches clinical starting line

...employees: About 120 Funds raised: $520 million Investors: Third Rock Ventures, D.E. Shaw Research, GV, Section 32...
BioCentury | Jan 12, 2020
Emerging Company Profile

Borisy newco aims to offer ‘radically’ cheaper drugs by disrupting biopharma’s traditional model

...$200 million in series A funding from GV, Arch Venture Partners, Andreessen Horowitz, Casdin Capital, Section 32...
BioCentury | Dec 13, 2019
Finance

Aspen’s debut reveals first cell therapy investment by Domain

...declined to disclose a fund-raising target. Alexandria Venture Investments, Arch Venture Partners, OrbiMed Advisors and Section 32...
Items per page:
1 - 10 of 34